Company news: Merck, Affymax, AstraZeneca
March 28 2012
Merck said Wednesday that its big outcomes study of cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) will be extended.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.